Search Results 1011-1020 of 16814 for monoclonal antibody

1. A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma - Mayo Clinic

   Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered from adverse events due to agents administered more than 4 ...

2. Trial to Assess Safety and Effectiveness of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) - Mayo Clinic

   ... antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory). Participation ...

3. Publications - Jeanne M. Palmer, M.D. - Mayo Clinic

   Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.

4. A Study to Evaluate Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer - Mayo Clinic

   Within 4 weeks (28 days): systemic cytotoxic chemotherapy; small molecule targeted agents with half-life ≥ 7 days; monoclonal antibodies, antibody-drug ...

5. A Study to Evaluate the Safety and Effectiveness of TEPEZZA® in Treating Patients with Chronic (Inactive) Thyroid Eye Disease - Mayo Clinic

   Treatment with any monoclonal antibody within 3 months prior to Screening. Identified pre-existing ophthalmic disease that, in the judgment of the ...

6. Role of Immunity in Efficacy of Chemotherapy Plus Trastuzumab - Mayo Clinic

   The purpose of this study is to evaluate T cell and antibody immunity in patients with HER2+ breast cancer who will receive trastuzumab with standard ...

7. A Study to Evaluate Effectiveness and Quality of Life Outcomes of Daratumumab in Relapsed/Refractory Multiple Myeloma Patients - Mayo Clinic

   Patients with history of prior daratumumab or another anti-CD38 monoclonal antibody treatment who were not refractory or intolerant to such therapy will be able ...

8. A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) - Mayo Clinic

   Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint inhibitors, other monoclonal antibodies, antibody-drug conjugates ...

9. Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers - Mayo Clinic

   Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI-CTC V4.03 or V5.0 for phase II part 2), any history of anaphylaxis, or ...

10. GEN3013, Epcoritamab Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma EPCORE™ NHL-1 - Mayo Clinic

    ... monoclonal antibody-containing therapy. Note: Relapsed disease is defined as disease that has recurred ≥6 months after completion of therapy. Refractory ...